SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who bought common stock between August 1, 2025 and May 15, 2026 have until September 14, 2026 to seek appointment as lead plaintiff in a proposed class action. Filed in the U.S. District Court for the Southern District of New York as Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026, the suit alleges Regeneron and senior executives violated the Securities Exchange Act of 1934. The complaint centers on statements about Regeneron’s Phase III Fianlimab-Libtayo study, including claims about flawed assumptions, risks to reaching the primary endpoint, and alleged trial underperformance. It points to stock drops after an April 29, 2026 earnings call and a May 15, 2026 press release.